Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Kenvue, Inc. ( (KVUE) ) is now available.
On July 14, 2025, Kenvue announced a significant leadership change with the departure of CEO Thibaut Mongon and the appointment of Kirk L. Perry as interim CEO. This transition is part of a broader strategy to unlock shareholder value and enhance company performance. The Board is conducting a comprehensive review of strategic alternatives to optimize Kenvue’s brand portfolio and improve operational execution. The strategic review is advised by Centerview Partners and McKinsey & Company, aiming to accelerate growth and value creation for shareholders.
The most recent analyst rating on (KVUE) stock is a Hold with a $23.50 price target. To see the full list of analyst forecasts on Kenvue, Inc. stock, see the KVUE Stock Forecast page.
Spark’s Take on KVUE Stock
According to Spark, TipRanks’ AI Analyst, KVUE is a Neutral.
Kenvue, Inc. scores a 68, driven by its solid financial health and strategic initiatives to enhance growth, despite facing valuation concerns and mixed earnings guidance. Technical indicators suggest potential buying opportunities, but high P/E indicates caution.
To see Spark’s full report on KVUE stock, click here.
More about Kenvue, Inc.
Kenvue is the world’s largest pure-play consumer health company by revenue, known for its iconic brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol. These brands are science-backed and recommended by healthcare professionals globally, emphasizing the power of everyday care.
Average Trading Volume: 19,048,548
Technical Sentiment Signal: Hold
Current Market Cap: $40.97B
For detailed information about KVUE stock, go to TipRanks’ Stock Analysis page.